– USA, CA – Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors, bringing nearly two decades of experience as biotechnology executive.
“Lyn is a well-respected biotechnology executive whose deep experience includes a diverse set of product portfolios and therapeutic areas,” said CEO, Talat Imran. “Lyn’s track record in creating strategic partnerships and executing complex financial transactions involving preclinical to commercial stage assets will be invaluable as we continue to advance our technology and grow the company.”
About Lyn Baranowski
Lyn Baranowski has 18 years of experience building, directing, and guiding biopharmaceutical companies. Currently, Ms. Baranowski serves as the COO at Altavant Sciences, a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Before Altavant, Ms. Baranowski served as the SVP, Corporate Development, and Strategy at Melinta Therapeutics, where she guided the company through significant milestones including the FDA’s approval of the company’s lead asset, a successful public listing, and acquisition of a key business unit from the Medicines Company. Before Melinta, Ms. Baranowski was the VP, Commercial Development at Pearl Therapeutics where she was instrumental in the company’s acquisition by AstraZeneca. Earlier in her career, Ms. Baranowski was VP at Vatera Healthcare, a VC/PE firm, and held a variety of roles in business development, marketing, and policy with Novartis Pharmaceuticals.
“The RaniPill is a disruptive technology with the potential to revolutionize the way biologics are delivered, and I am thrilled to be involved with a company at the forefront of replacing painful injections with pain-free, oral alternatives,” said Lyn Baranowski. “I look forward to leveraging my experience guiding strategic transactions to help Rani achieve its goals as the company progresses its development pipeline into and eventually through the clinic.”
Ms. Baranowski received her BA in international studies from American University as well as an MBA from Harvard Business School.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on the oral delivery of biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill capsule, a novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule.
For more information: https://www.ranitherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.